What Every Woman Should Know about Cervical Cancer (2^nd Ed., 2nd ed. 2016) Revised and Updated

This book (an updated and extended edition) is about mobilizing women and health care policy makers and providers to unite their efforts in a single strategy for fighting cervical cancer worldwide. The objective of this strategy would be to reverse cervical cancer prevalence and mortality rates among all 2.4 billion women at risk and to achieve this goal within 10-15 years of implementation. Cervical Cancer Screening (Pap test, VIA, VILI, or HPV) failed to stop cervical cancer worldwide simply because many countries could not afford developing infrastructure necessary to carry on the global strategy, and because the outreach could not accomplish the targeted 51% of the population at risk. In 2015, there is still 600,000 women getting cervical cancer annually and 300,000 of them die. Every minute one woman gets cervical cancer and every 2 minutes one woman dies from this preventable disease.

In 21^st Century the Information Technology (IT) Revolution has made substantial impact on medicine enabling remote points-of care, scattered around the world, to be e-connected with experts in distant medical centers and to obtain quality diagnosis and proper guidelines for curative therapy of early stages of cervical cancer. Low frequency of costly interventions needed makes IT-based screening financially and socially beneficial for mass screening.

This new Mobile Health technology with the Global Strategy for Fighting Cervical Cancer is subject to elaboration in our book as the new hope when old efforts have failed to stop the world ?epidemics? of this grave but preventable disease. The language is adapted for easy reading and understanding by professionals and lay-persons.

This book is intended for women at risk for cervical cancer, their health care providers, health insurance companies, government responsible for making health policy and healthcare industry because all of them have special role in the new Global Strategy elaborated in details in this book.

Prelims

PROLOGUE

  1.1 Basic Anatomy of the Female Reproductive System

1.1.1The Ovaries

1.1.2 Fallopian Tubes

1.1.3 The Uterus

1.1.4The Vagina

1.1.5The Vulva and the Perineum

1.2     Basic Physiology of the Female Reproductive System

1.2.1 Female Hormones

1.2.2 The Menstrual Cycle

1.2.3  Pregnancy

1.2.4  Menopause

1.3.   An Overview of the Most Common Women’s Diseases

1.3.1 Menstrual Disorders

1.3.2 Other Disorders

1.3.3 Common Infections in Women

1.3.4 Sexually Transmitted Diseases

1.4     Tumors of the Female Genital System

                1.4.1   Benign Tumors

1.  4.2. Malignant Tumors other than Cervical Cancer

2.1 About Cervical Cancer and Pre-carcinomatosis

       2.1.1 Introduction

2.12  Definition

2.13   Interpretation

2.2  Epidemiology of Cervical Cancer

2.3  Prevention and Control of Cervical Cancer

         2.3.1 Risk Factors and Education to Reduce Their Influence

         2.3.2 Cancer Control: Cervical Cancer/Pre-carcinomatosis

                   Screening

          2.3.3 Non-cytological based Cervical Cancer Screening

    2.3.4  Management of Women When the Pap test result Returns

2.3.5Biomarkers and Cervical Cancer

2.4  Diagnosis and Treatment of Cervical Cancer

2.4.1 Diagnostic Methods

       2.4.3   Planning Therapy

       2.4.4   Cervical Cancer Treatment

 2.5  Prognosis of Cervical Cancer and How to improve it

3.1   Cooping

3.1.2 The Diagnosis is Cervical Cancer

3.1.3 Support fro Caregivers and Close Family in Day-by-Day Coping with the Disease

3.1.4 Support of Extended Family and Friends

3.1.5  Support Groups

3.2   Living with Cancer

      3.2.1 Complementary and Alternative Medicine

3.2.3   Which are other dimensions of Health Described as a Holistic Health Model

3.2.4  How we can achieve A Higher Level of Wellness Across all Dimensions of Health?

3.2.5  Understanding the Mechanism of Stress

3.2.6  Stress Release Strategies

3.2.7   An overview on Eating for Optimal Health in Cancer Prevention and Cancer Prevention and Cervical Cancer

      3.4      Survey on What Women Think About Pap Test

            3.4.1   Background

3.4.2    Identifying  the Problem

3.4.3    Addressing the Problem

3.4.4    Study Results and Analysis

3.4.5    Conclusion

CHAPTER 4 

4.1. CURRENT PRACTICES

4.1.1     Afterward to the 2008 Edition:  What we have predicted

4.1.2     What happened with Pap test

4.1.2.1     Dethroning  classic Pap test

4.1.2.2      Disappointment with the global outreach

4.1.2.3     Failure of alternatives to repeat the success of the Pap test in the US

4.1.2.4     Attempt to balance the screening cost  with the benefit obtained

4.1.2.5     Search for new ideas to reverse the increasing cancer trends worldwide

4.1.2.6     Change of the WHO strategy

4.1.3    Pap test now

4.1.4    Challenges to standard Pap test – An overview

4.1.5   Liquid - based cervical cytology.

4.1.6 HPV testing and immunization

4.1.7 Management of women after Pap test

4.2 GUIDELINES

   4.2.1 Overview on Guidelines

   4.2.2 Individual Guidelines

         4.2.2.1 ACOG

         4.2.2.2 ASC 2015

         4.2.2.3 ASCCP

         4.2.2.4   USPSTF

         4.2.2.5 WHO

CHAPTER   5

GLOBAL CERVICAL CANCER SCREENING

5.1   Worldwide Application of Cervical Cancer Screening

5.2   Cervical Cancer Statistics-world

5.3    Gross Domestic Product per Capita

5.4     Study Summary

5.4.1     Examples

5.4.1.1             US India Symposium on Cervical Cancer

5.4.1.2             India Press Release 2015

5.4.1.3             Cervical Cancer in China Press Release 2015 

5.4.1.4    Republic of Serbia

5.4.2       Continents- World Summary

5.5.              Preliminary Data Pilot Study

5.6   Examples from Individual countries

   CHAPTER 6

   NEW STRATEGY and ITS GLOBAL APPLICATION

6.1        Executive Summary

6.2    Global Cervical Cancer Screening

6.2.1      Introduction

6.2.1.2     Which Strategy to Choose

6.2.1.3     New Strategy Applied for India

6.2.1.4      Instead of Conclusion

6.3   MarkPap® Technology Platform

6.4   Social Impact: LMIC and Alleviation of health disparity

6.5.1    Global Funding and Application of the New Strategy

6.5.2    Global Benefit

6.5.3    Socio-economic Advantage

6.6    Policy Change (India)

7.1.1 MarkPap®Test   

7.1.2 MarkPap® Reagent Kit with Accessories

            7.1.3 MarkPap® Specimen Collection Kit™

            7.1.4 MarkPap® Telecytopathology                        ``````````7.1.5 MarkPap® Digital (Tele -Pap)

7.1.6    MarkPap® Mobile

7.2       IT Telehealth Center (ITTHC)

7.3       The New Integrative Complex MEDYKO

       7.3.1    Concept

7.3.2          Letter

7.3.3          Methods Comparison

7.4       TEMPLATE for Telecytopathology

7.5       Screen and Treat with MarkPap

7.6       Telecytopathology Protocol

Chapter 8     REFERENCES

8.1  Ethics

8.2   Literature Cited

8.3   Where to Read More

8.4   Index

8.5  EPILOGUE

9.1 Brochures

9.1.1  MarkPap India, LLC.  Fighting Cervical Cancer.

   Brochure, 2012

9.1.2  MarkPap Pacific, LLC. Cervical Cancer in China. Brochure. How we can help. 2013

9.2   Power Point Presentations

9.2.1  National Institute for Standards and Technology (NIST).

Lecture on MarkPap Technology, 2014

9.2.2  Global Health Challenges: Is worldwide cytological cervical screening possible? 2105

9.2.3MarkPap Pacific presents: MarkPap® Technology, 2013

9.2.4   China Deal Overview. MarkPap Pacific, LLC, 2009

<9.2.5. MarkPap Pacific, LLC. Opportunity in China, 2008

9.2.6MarkPap India, LLC. Cervical Cancer. How we can help. 2012

9.2.7  BioSciCon, Inc. Special strategies for fighting cervical cancer in India. 2015

Actuality of the subject

One-stop comprehensive cervical cancer resource

Novelties in the field heralding future policy and standards

Personal position of authors on controversial issues

Balancing needs for developed and developing countries